Nurse-Led Program Demonstrates Initial Success in Reducing Severe Immune-Related Toxicity in Melanoma

Source: Oncology Nursing News, February 2022

Weekly phone calls from RNs helped reduce the number of severe adverse events experienced by patients receiving ipilimumab for metastatic melanoma.

A proactive nurse-led monitoring program helped patients with metastatic melanoma receiving ipilimumab (Yervoy) successfully maintain low rates of severe toxicity, although disease-related hospitalization rates remained high, according to findings published in the Journal of Clinical Oncology.1